Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10689383B2 · kind B2 · utility
4Cited by
3References
59Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 31, 2015 |
| Grant date | Jun 23, 2020 |
| Priority date | — |
| Expiry date | Jul 31, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of Formula I, which are active toward nuclear receptors such as nuclear retinoic acid receptor-related orphan receptors (RORs), pharmaceutical compositions containing the compounds of Formula I, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the of the compounds Formula I in therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.